PUBLICATION

Global Business Reports

AUTHORS

Irina Negoita, James Hogan, Lubo Novak, Karl Reilly

Taiwan Pharmaceuticals & Biotechnology 2015

June 16, 2015

If government support is considered to be fundamental to an industry’s success, as could be argued in the case of the Taiwan’s information technology industry, the country’s pharmaceuticals and biotechnology industry is well positioned, as the government’s support cannot be questioned over the course of the last three decades. From 1984 to 2013, the National Development Fund, Taiwan’s government backed investment fund, has invested NT$12.4 billion into the pharmaceutical and biotechnology sector, including direct investments of NT$4.7 billion into thirteen pharmaceutical and biotechnology companies and a further NT$7.7 billion into twenty-four biotech-focused venture capital firms.

Aside from a supportive government, Taiwan offers a host of benefits that make it very attractive for future investors. Taiwan’s geographic location makes it an effective entry point for foreign companies that are interested in Asian markets, including China. PIC/S compliance, a high number of English speakers and research excellence have resulted in an extensive pipeline of potential breakthrough drugs. Taiwan’s most important strength may be its people, who provide an extensive talent pool which is being further enriched by the return of many highly skilled and successful Taiwanese from countries such as the United States.

 

Featuring exclusive interviews with:

Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO), MOEA – Dr. Chien-Hsin Daniel Cheng, Former Director
Ministry of Health and Welfare (MOHW), Government of Taiwan – Dr. Ming-Neng Shiu, Vice-Minister
Taiwan Bio Industry Organization (TBIO) – Dr. Johnsee Lee, Honorary Chairman
Taiwan Generic Pharmaceutical Association (TGPA) – Samuel Wang, President
Taiwan Food and Drug Administration (TFDA) – Dr. Shiow-Ing Wu, Deputy Director-General
Pfizer Taiwan – Kevin Liu, Director of PAP&C and Market Access
GlaxoSmithKline (GSK) – René Jensen, Vice President and General Manager
PwC Taiwan – Lily Wong, Advisory Partner and Health Industries Leader
Lotus Pharmaceutical Co. – Renaat Janssen, CEO
Standard Chem. & Pharm. Co. – Roy Fan, CEO
Formosa Laboratories – Dr. C.Y. Cheng, President
Taigen Biotechnology – Dr. Ming-Chu Hsu, Chairman and CEO

RELATED INTERVIEWS MORE INTERVIEWS

Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.
Piramal Pharma updates GBR in its recent developments and prospects.
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.

RECENT PUBLICATIONS

MACIG 2025 - Mining in Africa Country Investment Guide

It is said that mining is a patient industry. Current demand projections are not. Demand for minerals deemed ‘critical’ is set to increase almost fourfold by 2030, according to the UN. Demand for nickel, cobalt and lithium is predicted to double, triple and rise ten-fold, respectively, between 2022 and 2050. The world will need to mine more copper between 2018 and 2050 than it has mined throughout history. 2050 is also the deadline to curb emissions before reaching a point of ‘no return.’ The pace of mineral demand and the consequences of not meeting it force the industry to act fast and take more risks. Mining cannot afford to be a patient industry anymore. The scramble for supply drives miners back to geological credentials, and therefore to places like the African Central Copperbelt.

MORE PREVIOUSLY PUBLISHED

MACIG

"Ukwazi means 'to know' in Zulu, and our specialist teams and industry experts integrate multiple knowledge disciplines."

SUBSCRIBE TO OUR NEWSLETTER